A Study of LY3023414 in Participants With Advanced Cancer
Completed · Phase 1 · NCT01655225
Conditions: Advanced Cancer, Metastatic Cancer, Non-Hodgkin's Lymphoma, Metastatic Breast Cancer, Malignant Mesothelioma, Non-small Cell Lung Cancer
At a glance
- Research payments reported, 2025
- $8,977
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 156
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- LY3023414 (drug), Midazolam (drug), Fulvestrant (drug), Pemetrexed (drug), Cisplatin (drug), Abemaciclib (drug), Letrozole (drug)
- Dates
- Started 2012-07-31; completion 2022-02-02
- Results posted
- Not yet
The purpose of this study is to find a recommended dose level and schedule of dosing LY3023414 that can safely be taken by participants with advanced or metastatic cancer. The study will also explore the changes to various markers in blood cells and potentially tumor cells. Finally, the study will help document any antitumor activity this drug may have. In Part A of this study, participants with advanced/metastatic cancer (including lymphoma) will receive increasing doses of LY3023414. In Part B, LY3023414 will be explored in different types of cancer, including breast and lung cancer, lymphoma and mesothelioma.
From ClinicalTrials.gov, last updated 2022-04-08. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $8,977 in research payments for this study in 2025 (1 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- State of Oklahoma Board of Regents of the University of Oklahoma $8,977
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.